Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston
5
×
boston blog main
boston top stories
life sciences
national blog main
alnylam pharmaceuticals
clinical trials
rna interference
drugs
fda
national top stories
onpattro
patisiran
akcea therapeutics
aminolevulinic acid
givosiran
hereditary transthyretin amyloidosis
inotersen
new york blog main
new york top stories
pfizer
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
tafamidis
accelerated approval
acute hepatic porphyria
acute hepatic porphyrias
akin akinc
alexion pharmaceuticals
alnylam pharmaceutials
andrew fire
arrowhead pharmaceuticals
biotech
boehringer ingelheim
craig mello
deals
dicerna pharmaceuticals
eli lilly
What
rnai
5
×
alnylam
drug
interference
medicine
rna
fda
pharmaceuticals
ago
gets
ok
second
seek
speedy
abandoning
afternoon
alnylam’s
approval
approved
approves
baggage
cells
cleared
companies
cuts
data
deal
development
dicerna
ema
employ
europe
far
follows
free
gene
harmful
history
hits
indicated
Language
Current search:
boston
×
rnai
×
@xconomy.com
5 years ago
Free of Baggage, Dicerna Cuts Another RNAi Deal and Gets $200M
@xconomy.com
5 years ago
Alnylam Won’t Seek Quick FDA Nod For Second RNAi Drug
@xconomy.com
5 years ago
With New Data, Alnylam Could Seek Speedy OK For Second RNAi Drug
@xconomy.com
5 years ago
RNAi Hits Europe as EMA Follows FDA, Approves Alnylam Drug
@xconomy.com
5 years ago
Alnylam Gets Landmark FDA OK For First-Ever RNAi Drug